-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode Therapeutics Announces 1-For-28 Reverse Stock Split; The Effective Date Of The Reverse Stock Split Has Not Yet Been Determined

Benzinga·05/02/2025 20:11:03
Listen to the news

Split designed to achieve compliance with Nasdaq minimum bid price requirements

BOSTON, May 2, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-28 reverse stock split. The reverse stock split was approved by TransCode's stockholders on May 2, 2025, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.